Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of CHOP [cyclophosphamide, doxorubicin, vincristine and prednisone] plus rituximab vs CHOP plus iodine-131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas

X
Trial Profile

A phase III trial of CHOP [cyclophosphamide, doxorubicin, vincristine and prednisone] plus rituximab vs CHOP plus iodine-131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jun 2024 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
    • 31 May 2024 According to an Adaptive Biotechnologies media release, results from this trial, to be presented at the European Hematology Association (EHA) Hybrid Congress taking place June 13-16 in Madrid and virtually.
    • 12 Dec 2023 Results discussing MRD analysis by ClonoSeq assay predicts outcomes in a prospective cohort of patients with advanced stage FL, presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top